For semaglutide, Novo Nordisk filed the composition patent in December 2003 (issued as US 8,927,488 in 2015), giving a base expiration of December 2023
Know your baseline risk Before starting semaglutide, discuss your personal blood clot risk with your healthcare provider
For the broader management of obesity in the UK, clinicians should refer to the current NICE obesity guideline and relevant technology appraisals for authorised weight-management medicines (for example, TA875 for semaglutide 2.4 mg for weight management)
studies show that glutathione may help to treat fatty liver (NAFLD) because of its detoxification and antioxidant properties
Understanding how these drugs work provides essential context for their elimination from the body
By enhancing insulin sensitivity in adipose tissue and skeletal muscle, these agents reduce secretion of pro-inflammatory adipokines while concurrently elevating adiponectin an anti-inflammatory hormone whose levels are characteristically suppressed in obesity